Three biopharmaceutical companies launched US initial public offerings in January, kicking off 2017 with more confidence than drug developers showed in 2016 when there were no biopharma IPOs during the first month of the year.
With the AnaptysBio Inc., Jounce Therapeutics Inc. and ObsEva SA offerings in January, 2017 is a bit ahead of 2016, which had 30 biopharma IPOs – an average of 2.5 per month
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?